Oklahoma is increasingly positioning itself as a hub for life sciences innovation, industry leaders said during Life Science Oklahoma’s networking breakfast at the 2026 BIO International Convention in San Diego. Panelists argued the state’s mix of research capacity, expanding manufacturing and coordinated workforce programs is creating real options for companies that previously left the region to scale.
The session put a spotlight on how local organizations, investors and universities are aligning to keep the full development pipeline—from discovery to commercial production—within Oklahoma’s borders.
Moderated by Tabari Baker, chief executive of Kronos Scientifica, the panel included executives from several homegrown and national firms: Craig Shimasaki of Molecular Biosciences, Patrick Lucy of Wheeler Bio, Tom Kupiek of ARL Bio Pharma, Rose Rhomberg of Cytovance Biologics and Marcos Bazanna from Tulsa Innovation Labs. Together they discussed the building blocks now shaping the state’s bioscience landscape.
Meridian BID could reshape Oklahoma City corridor: plan promises safer streets and more businesses
High school football week zero: standout players and key takeaways
Speakers cited major regional research institutions—such as the Oklahoma Medical Research Foundation, the University of Oklahoma, OU Health and the Stephenson Cancer Center—as sources of scientific talent and early-stage projects that feed the local economy. They also described growing private-sector capacity to take discoveries all the way to manufactured therapies.
That chain of support matters because it reduces the need for startups to relocate in order to access specialized facilities or skilled workers. Panelists said this shift could accelerate commercialization timelines and retain investment in-state.
Key drivers identified at the breakfast:
- Research institutions producing translational science and trained professionals.
- Biomanufacturing infrastructure that enables local production of biologics and other therapies.
- Workforce development programs aligned with industry needs to fill technical roles.
- Investor and commercialization activity that offers capital and mentorship for early-stage companies.
- Cross-sector collaboration among public, private and academic partners to lower barriers for growth.
Executives at the table emphasized culture as a differentiator. Rather than treating fledgling companies as too small to merit attention, Oklahoma’s ecosystem — they said — tends to pool resources and expertise to nurture promising projects through the risky early phases.
“When local stakeholders see potential in an enterprise, they often step in to provide practical support so it can scale,” said one participant, noting that community investment can be as important as institutional funding. Panelists described this cooperative mindset as a reason companies can begin development and remain in the state for later-stage work.
Practical outcomes are already visible: new manufacturing capacity, training programs designed with industry input, and a gradual rise in commercialization-focused funding. Collectively, those elements lower the friction for founders and may help Oklahoma compete with long-established biotech centers.
Looking ahead, panelists said sustaining momentum will depend on continued alignment between universities, private companies and state leaders to expand facilities, deepen talent pipelines and attract outside capital. If those pieces hold, Oklahoma could offer an increasingly attractive, lower-cost alternative for life sciences firms seeking to develop and make therapies without leaving the region.
